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Abstract Although inositol lipids constitute only a very minor
proportion of total cellular lipids, they have received immense
attention by scientists since it was discovered that they play key
roles in a wide range of important cellular processes. In the late
1980s, it was suggested that these lipids are also present within
the cell nucleus. Albeit the early reports about the intranuclear
localization of phosphoinositides were met by skepticism and
disbelief, compelling evidence has subsequently been accumulated
convincingly showing that a phosphoinositide cycle is present at
the nuclear level and may be activated in response to stimuli that
do not activate the inositol lipid metabolism localized at the
plasma membrane. Very recently, intriguing new data have
highlighted that some of the mechanisms regulating nuclear
inositol lipid metabolism differ in a substantial way from those
operating at the cell periphery. Here, we provide an overview
of recent findings regarding the regulation of both nuclear
phosphatidylinositol 3-kinase and phosphoinositide-specific phos-
pholipase C-L1. ß 2001 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Inositol phospholipids represent a very minor fraction of
cell phospholipids, yet they are involved in a number of key
functions in several signaling pathways and in membrane traf-
¢c [1,2]. Indeed, it is hard to ¢nd a cell process in which
inositol phospholipids have not been implicated. In the ‘can-
onical’ inositol lipid cycle, phosphatidylinositol 4,5-bisphos-
phate (PtdIns(4,5)P2) is hydrolyzed by means of a phospho-
inositide-speci¢c phospholipase C (PI-PLC) in response to a
wide variety of stimuli, including growth factors, hormones,
and neurotransmitters, that act on speci¢c receptors localized
at the plasma membrane. This reaction generates two second
messengers of paramount importance, 1,2-diacylglycerol
(DAG) and inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) [3,4].
The former may either activate DAG-dependent protein ki-
nase C (PKC) isoforms or be converted to phosphatidic acid,
which also has signaling functions; the latter liberates Ca2
from intracellular stores [5]. More recently, the discovery of
the D-3 phosphorylated inositides, such as phosphatidylinosi-
tol 3,4,5-trisphosphate (PtdIns(3,4,5)P3), and the enzyme
which synthesizes them, i.e. phosphatidylinositol 3-kinase
(PI3K), has considerably renewed the interest of cell and mo-
lecular biologists for phosphatidylinositol metabolism [6]. D-3
phosphorylated inositides are not substrates for phospholi-
pases, but serve as second messengers themselves and regulate
a plethora of cell functions.
Since the late 1980s, it was suggested that similar inositol
lipid metabolism operates within the nucleus [7]. These early
¢ndings were met with disbelief, and rightly so, because it was
generally thought to be the consequence of nuclear prepara-
tions being contaminated with residues of the plasma mem-
brane. Indeed, the isolation of any intracellular organelle is
always likely to su¡er from di¡erent degrees of contamination
with other organelles. However, in the following years, data
coming from independent laboratories (reviewed in [8^12])
unequivocally demonstrated that the nucleus is endowed
with its own inositide cycle. The recent widespread use of
molecular biology techniques has greatly contributed to the
demonstration that the results regarding nuclear inositide
cycle are not a consequence of contamination. A characteristic
feature of the inositol lipid cycle present in the nucleus is its
operational distinctiveness from the cycle present at the plas-
ma membrane. In other words, many agonists that stimulate
the membrane cycle do not activate the nuclear cycle and vice
versa. In other cases, if an agonist stimulates both cycles, it
does so in a temporally distinct manner [8^12].
Since the nucleus contains inositol lipid cycle enzymes that
are apparently the same as those involved at the plasma mem-
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brane level, it was assumed that their regulation should be
similar. However, recent studies have highlighted that the reg-
ulation of the nuclear polyphosphoinositide metabolism may
be quite di¡erent from the plasma membrane cycle.
Here, we shall review the most recent ¢ndings regarding the
regulation of nuclear PI3K and PI-PLC-L1, i.e. two key en-
zymes of the inositol lipid cycle. These data further strengthen
the notion that the nuclear polyphosphoinositide metabolism
is independent of the plasma membrane cycle.
2. Nuclear D-3 phosphorylated inositides and PI3K
The D-3 phosphorylated inositides found in mammalian
cells are PtdIns(3)P, PtdIns(3,4)P2, PtdIns(3,5)P2, and
PtdIns(3,4,5)P3. Resting mammalian cells contain signi¢cant
levels of PtdIns(3)P, but hardly any of the other D-3 phos-
phorylated inositides. While the overall levels of PtdIns(3)P
do almost not increase upon cell stimulation, the levels of the
other D-3 phosphorylated inositides can rise sharply [13].
Even though these lipid molecules are not the target of any
known phospholipases, they are metabolized by phosphatases
that act on the inositol ring. PTEN is a 3P-phosphatase which
has received a lot of attention recently, because it was previ-
ously identi¢ed as a tumor suppressor gene. PTEN con-
verts PtdIns(3,4)P2 to PtdIns(4)P, and PtdIns(3,4,5)P3 to
PtdIns(4,5)P2. In a signi¢cant number of human cancers,
PTEN is mutated and inactivated so that PI3K signaling is
constitutively activated as a result of the high PtdIns(3,4,5)P3
levels [14].
There are multiple isoforms of PI3K in mammalian cells,
and these are subdivided into three classes, referred to as I, II,
and III [6,13]. The most studied are class I PI3Ks, because
they are generally coupled to extracellular stimuli. They dis-
play a preference in vivo for PtdIns(4,5)P2. Class IA PI3Ks
consist of a p110 catalytic subunit (K, L, and N) and a p85
regulatory adaptor subunit (K, L). In contrast, class IB PI3K
or PI3KQ is made of a p110Q catalytic subunit and a p101
regulatory subunit, unrelated to p85. p110Q can be activated
in vitro by the LQ subunits of heterotrimeric G proteins [6].
A number of reports have highlighted the presence of PI3K
in the nucleus of di¡erent cell types, including neurons, hepa-
tocytes, human osteosarcoma and promyelocytic leukemia
cells (reviewed in [10,12]). Both class IA (e.g. [15]) and class
IB (e.g. [16]) PI3Ks have been detected in the nucleus or
translocate there in response to various stimuli. Moreover,
Bacqueville et al. [17] have shown the presence of a 117-
kDa PI3K, immunologically related to p110Q, in the nucleus
of pig aorta vascular smooth muscle cells.
Very recently, the presence of a class II PI3K, PI3K C2L,
has been reported in the rat hepatocyte nucleus [18]. Interest-
ingly, PI3K C2L activity increased at 20 h after partial hep-
atectomy, suggesting it plays a role in liver regeneration. In-
tranuclear PI3K is not restricted to mammalian cells, because
this kinase has also been found in nuclei of plant cells, where
it colocalizes with transcription sites, an indication that this
enzyme might be important for mRNA synthesis [19]. Fur-
thermore, the occurrence in the nucleus of D-3 phosphorylat-
ed inositol lipids has been reported by means of techniques
ranging from in vivo labeling with [32P]orthophosphate
[20,21], to immunostaining with speci¢c monoclonal antibod-
ies [22], to the use of FYVE domain probes [23]. It is worth
recalling here that the nucleus also contains other components
of the PI3K signaling pathways, such as PKC-j [21,24], PKB/
Akt [25], and PTEN [26]. However, the functional signi¢cance
of these intranuclear pathways remains to be elucidated.
2.1. The regulation of nuclear PI3K
While control of cytoplasmic PI3K is quite well de¢ned
(e.g. [6]), regulation of nuclear PI3K has been obscure. In
some cases, however, it does not seem to di¡er in a substantial
way from what happens in the cytoplasm. Indeed, nuclear
PI3KQ is sensitive to pertussis toxin, an indication that nuclear
Gi/G0 proteins are likely to be involved in its activation [17],
while PI3K C2L, which has been found in the nucleus, is
conceivably activated through calpain-mediated proteolysis,
as reported for platelets [18]. Indeed, in normal liver PI3K
C2L bands at approximately 180 kDa, whereas 20 h after
partial hepatectomy (when maximal PI3K was measured) a
18-kDa gel shift was observed [18].
A major breakthrough has recently been achieved regarding
the control of class IA nuclear PI3K in PC12 cells stimulated
with nerve growth factor (NGF). By means of yeast two-hy-
brid analysis it has been identi¢ed as a novel nuclear 753-
amino acid GTPase, named PIKE (for phosphoinositide
kinase enhancer), which binds to the p85 regulatory subunit
of PI3K, resulting in activation of the catalytic subunit [27].
The amino acid sequence of PIKE displays in its carboxy-
terminal portion a substantial homology to several G pro-
teins, such as centaurin Q-a, Rab7, or R-Ras. PIKE also pos-
sesses a pleckstrin homology (PH) domain. By Northern blot
analysis of rat tissues, PIKE was found to be mostly abun-
dantly expressed in brain, and to a lesser extent also in lung,
heart, and liver. When an epitope-tagged PIKE was overex-
pressed in HEK293 cells, it localized exclusively to the nu-
cleus. NGF treatment of PC12 cells led to a ¢ve-fold increase
in PIKE binding to GTP. Binding of PIKE to the p85 regu-
latory subunit of PI3K depends on both the amino terminal
261 amino acids and on the carboxy-terminal 40% of the
GTPase, but not on its PH domain. PIKE also binds to the
p110 catalytic subunit of PI3K, but in this case removal of the
carboxy-terminal 40% of PIKE only modestly reduces binding
(see Fig. 1). In cells transfected with p110 and PIKE, but
lacking p85, no enhancement of PI3K activity was measured,
demonstrating that p85 is required for the activation. At a
¢rst glance, this mechanism of activation of nuclear PI3K
might appear similar to that reported for cytoplasmic PI3K,
which can be stimulated by Ras (see [6] and references there-
in). However, in the case of the PI3K/Ras interaction, only
the p110 catalytic subunit binds Ras, while PIKE binds both
p110 and p85. Indeed, as emphasized above, p85 is absolutely
required for PIKE-mediated activation of nuclear PI3K. Ye
and coworkers [27] went further and demonstrated that pro-
tein 4.1N blocks the activation of PI3K by preventing PIKE
association with PI3K. Protein 4.1N is a neuronal selective
isoform of the erythrocyte membrane cytoskeleton protein
4.1R [28]. Protein 4.1N resides in the cytoplasm, and follow-
ing challenging of PC12 cells with NGF, migrates to the nu-
cleus over a period of hours, lagging behind PI3K transloca-
tion to the nucleus, which occurs within 30 min of
stimulation. In contrast, it is currently thought that inhibition
of plasma membrane class IA PI3K is mostly achieved
through tyrosine dephosphorylation of growth factor recep-
tor, which p85 binds to with its SH2 domains. In addition, a
signal regulatory protein which negatively a¡ects plasma
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membrane PI3K activity is SIRPK1. This protein was shown
to reduce the association between phosphotyrosine phospha-
tase SHP2 and the p85 regulatory subunit of PI3K [29].
This mode of control of nuclear PI3K activity is extremely
intriguing, but some questions remain unsettled. Firstly, it is
not clear which protein activates the PIKE GTPase within the
nucleus. Secondly, in many cell types, protein 4.1N is consti-
tutively present in the nucleus, where it binds the abundant
nuclear matrix protein NuMA (e.g. [30^32]). Moreover, 4.1N
is concentrated in the speckless domains of the nucleus where
it is involved in mRNA splicing [33,34]. However, in PC12
cells, 4.1N is scarcely expressed in the nucleus under basal
conditions and translocates there in response to NGF [28].
Therefore, it remains to be established whether this kind of
activation of nuclear class IA PI3K is universal or restricted
to a single cell type. Thirdly, we and others [15,20] have re-
ported a massive tyrosine phosphorylation of p85 recovered in
the nucleus. Such a phosphorylation might somehow facilitate
binding of PIKE to the regulatory subunit of PI3K, although
its functional signi¢cance remains unclear. Thus, this issue
needs additional investigation.
3. Nuclear PI-PLC-L1
PI-PLC-L isoforms function as receptors belonging to the
rhodopsin superfamily of transmembrane proteins containing
seven transmembrane spanning segments. PI-PLC-L1/L4 are
activated by members of the Kq subfamily of the G proteins
K subunit and, except for the L4 isoform, by G proteins LQ
dimers (see [35] for an updated review on the issue). More-
over, in neutrophils, PI-PLC-L2 was found to be stimulated
by the Rho GTPases CdC42Hs and Rac1 [36]. PI-PLC-L1
mainly hydrolyzes PtdIns(4,5)P2, thus yielding DAG and
Ins(1,4,5)P3 [35].
PI-PLC-L1 was the inositide-speci¢c phospholipase origi-
nally identi¢ed at the nuclear level [37,38]. It is now estab-
lished that nuclear PI-PLC-L1 plays an important role in the
control of cell proliferation, because it mediates the mitogenic
e¡ect of insulin-like growth factor-I (IGF-I) in Swiss 3T3 cells
[39], or regulates cell cycle progression in mouse erythroleu-
kemia (MEL) cells [40,41]. In IGF-I-stimulated Swiss 3T3,
nuclear PI-PLC-L1 is responsible for the rise in the DAG
mass which occurs in the nucleus. Such an increase in the
DAG levels attracts to the nucleus the K isoform of PKC
(see also later) [39]. Moreover, it has recently been proposed
that PI-PLC-L1 is critically involved in resumption of meiosis
in mouse oocyte [42].
3.1. The regulation of nuclear PI-PLC-L1
Activation of nuclear PI-PLC-L1 by G proteins seemed un-
likely, given that nobody has ever demonstrated the presence
within the nucleus of GTP-binding proteins of the Gq class.
Nevertheless, in response to growth factor stimulation, the
whole heterotrimeric GTP-binding protein Gi translocated
to the nucleus [43], so that its LQ dimer might activate a
nuclear PI-PLC-L isoform. Consistently, we always failed to
stimulate nuclear PI-PLC-L1 activity with either GTP-Q-S or
AlF4 [44]. In contrast, GTP-Q-S stimulated polyphosphoinosi-
tide synthesis in isolated nuclei prepared from MEL cells,
suggesting that inositol lipid phosphorylation in the nucleus
Fig. 1. Proposed models outlining the activation/inhibition of nuclear PI-PLC-L1 and PI3K. Various agonists (IGF-I, insulin, and interleukin-2
(IL-2)) activate the MAP kinase pathway. Activated MAP kinase migrates to the nucleus where it phosphorylates PI-PLC-L1 at serine 982,
causing its activation. DAG produced by PtdIns(4,5)P2 hydrolysis attracts to the nucleus PKC-K. PKC-K phosphorylates PI-PLC-L1 at serine
887, producing its inhibition. In PC12 cells, NGF treatment activates the nuclear GTPase PIKE, which binds to both p85 and p110 subunits
of nuclear PI3K, thus activating it. Later on, protein 4.1N enters the nucleus and blocks PIKE interaction with PI3K, causing its inhibition.
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may be under the control of G proteins, in analogy with the
plasma membrane [45].
Thus, we sought to determine whether or not other mech-
anisms could control the activity of nuclear PI-PLC-L1. Phos-
phorylation is a widely used mechanism for reversibly regulat-
ing protein structure and function. Conformational or
electrostatic changes promoted by phosphorylation modulate
the enzymatic activity and macromolecular interactions of a
plethora of cellular proteins (e.g. [46]). Our laboratory dem-
onstrated for the ¢rst time that in response to IGF-I stimula-
tion of quiescent Swiss 3T3 cells, activation of nuclear
PI-PLC-L1 was paralleled by its hyperphosphorylation. Inter-
estingly, if nuclear translocation of p42/44 mitogen-activated
protein (MAP) kinase was prevented by cytoskeletal depoly-
merization, the hyperphosphorylation of PI-PLC-L1 was no
longer detectable, suggesting an involvement of MAP kinase
in this phenomenon [47]. Similar results have subsequently
been obtained with either insulin-treated NIH 3T3 cells [48]
or interleukin-2-exposed human natural killer cells [49]. In
these two reports, it was shown that activation of nuclear
PI-PLC-L1 was prevented by treatment of cells with
PD98059, a speci¢c inhibitor of MAP kinase kinase, a further
indication of the importance of the MAP kinase pathway. It is
important to recall that in insulin-treated NIH 3T3 ¢bro-
blasts, we observed a hyperphosphorylation of PI-PLC-L1b,
i.e. the form which is more abundantly expressed within the
nucleus [39].
However, the conclusive demonstration that p42/44 MAP
kinase was responsible for the activation of nuclear PI-PLC-
L1 came only very recently from a series of experiments, per-
formed with IGF-I-treated Swiss 3T3 cells, showing that:
(a) nuclear PI-PLC-L1 and activated p42/44 MAP kinase
could be coimmunoprecipitated; (b) recombinant PI-PLC-L1
could be e⁄ciently phosphorylated in vitro by activated
p42/44 MAP kinase, but not by protein kinase A (PKA);
(c) the p42/44 MAP kinase phosphorylation site of PI-PLC-
L1 was mapped at serine 982, which lies within a PSSP motif
located in the carboxy-terminal tail of PI-PLC-L1; (d) phos-
phopeptide analysis showed a similarity between in vivo
32P-labeled PI-PLC-L1 and PI-PLC-L1 phosphorylated in vi-
tro by p42/44 MAP kinase; (e) if Swiss 3T3 cells overex-
pressed a mutant PI-PLC-L1 in which serine 982 was replaced
by glycine, nuclear phospholipase activity was not activated
by IGF-I, and the mitogenic e¡ect of the growth factor was
markedly attenuated. Taken together, these ¢ndings unequiv-
ocally suggested that p42/44 MAP kinase phosphorylates nu-
clear PI-PLC-L1 at serine 982, and such a phosphorylation
plays a critical role in the activation of the phospholipase
and is also crucial to the mitogenic action of IGF-I [50]. These
¢ndings appear very intriguing and completely unexpected, as
they have never been reported for membrane-associated
PI-PLC-L1. Since the p42/44 MAP kinase phosphorylation
site is within the carboxyl terminus of PI-PLC-L1 (which
has been shown to be essential for its GKq-mediated activa-
tion at the plasma membrane) it is conceivable that this phos-
phorylative event may a¡ect the binding to this region of
other, as-yet-unidenti¢ed, nuclear proteins that consequently
stimulate phospholipase activity. Indeed, the MAP kinase-
mediated phosphorylation does not increase the in vitro ac-
tivity of puri¢ed PI-PLC-L1.
Phosphorylation of PI-PLC-L1 is not per se an entirely new
regulatory mechanism, because at the plasma membrane it is
utilized to inhibit PI-PLC activity. PKA has been shown to
directly phosphorylate in vitro PI-PLC-L2 or -L3, thereby in-
hibiting their activation by GLQ subunits. Here, the putative
phosphorylation site is serine 954, which determines an un-
coupling of receptors that activate PI-PLC-L3 through Gi/Go
while preserving the activation by receptors that utilize Gq.
However, PKA can phosphorylate PI-PLC-L3 also at serine
1105, and in this case the outcome is a partial block of the
Gq-dependent activation [41]. Moreover, PI-PLC-L isoforms
are also substrates for PKC. It was initially demonstrated that
treatment of a variety of cells with phorbol esters (that are
powerful PKC activators) resulted in the inhibition of recep-
tor-coupled PI-PLC-L activity. Moreover, PKC phosphorylat-
ed in vitro bovine PI-PLC-L at serine 887, but without any
concomitant e¡ect on phospholipase activity, so that the
physiological relevance of this phosphorylative event re-
mained unclear [51]. Subsequently, it has been shown that
PKC-K and -O (but not PKC-j) phosphorylated in vitro
PI-PLC-L1, whereas PI-PLC-L3 was poorly phosphorylated
by PKC-K [52]. In this case, PKC phosphorylation of
PI-PLC-L1 resulted in signi¢cant activity inhibition, but the
GKq stimulation was una¡ected, while GLQ subunits blocked
the PKC-K-mediated phosphorylation of PI-PLC-L1 and
antagonized its inhibition.
Translocation of PKC-K to the nucleus is one of the earliest
events that occur in IGF-I-treated Swiss 3T3 cells [53]. DAG
produced by nuclear PI-PLC-L1 serves as a chemoattractant
for PKC-K [37,54]. The functions of PKC-K, once translo-
cated in the nucleus, are unclear, but recent evidence indicates
it may be involved in a negative-feedback regulation of
PI-PLC-L1 activity [55]. Indeed, treatment of Swiss 3T3 cells
with Go6976, a selective inhibitor of PKC-K, caused a sus-
tained elevation of IGF-I-dependent PI-PLC-L1 activity.
Two-dimensional phosphopeptide mapping and site-directed
mutagenesis demonstrated that PKC-K phosphorylated nu-
clear PI-PLC-L1 at serine 887. Moreover, overexpression of
either a PI-PLC-L1 mutant in which the PKC phosphoryla-
tion site serine 887 was replaced by alanine, or a dominant-
negative PKC-K, resulted in a sustained activation of nuclear
PI-PLC-L1 in response to IGF-I stimulation. All in all, these
¢ndings indicated that a negative-feedback regulation of nu-
clear PI-PLC-L1 by PKC-K is a critical step in the termination
of the IGF-I-evoked signals that activated inositol lipid cycle
within the nucleus. However, an explanation of how phos-
phorylation of nuclear PI-PLC-L1 at serine 887 can modulate
its activity remains to be de¢ned. As reported above, there is
no evidence that a G protein is involved in the regulation of
nuclear PI-PLC-L1 activity, while in vitro phosphorylation of
puri¢ed PI-PLC-L1 by PKC-K seems to a¡ect the interaction
of the phospholipase with the GLQ subunits. It might be that
also in this case PI-PLC-L1 phosphorylation leads to changes
in the its interaction with other regulatory nuclear protein(s)
that remain to be identi¢ed.
4. Concluding remarks and future perspectives
Since the ¢rst observations that nuclei contain an inositol
lipid cycle, considerable e¡ort has been devoted to identifying
the regulatory mechanisms of the enzymes involved in this
metabolism. It now appears that inositol lipid metabolism
within the nucleus is at least as complex as that within the
cytoplasm. The progress made in de¢ning the molecular
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mechanisms of regulation of nuclear inositol lipid cycle has
been painfully slow when compared with the spectacular pro-
gresses achieved for its cytoplasmic counterpart. The main
reason why we know relatively little about these mechanisms
it is that they are very di⁄cult to study, as anyone who has
tried to do so will testify. In spite of all the technical di⁄cul-
ties, since the pioneer days of nuclear inositol lipid signaling, a
radical change has happened: we now have many new tech-
niques and tools to study at the molecular level the events
taking place within the nucleus. It is also true that our knowl-
edge of similar pathways and processes outside the nucleus
has tremendously advanced. Therefore, over the last few
months, our comprehension of the molecular mechanisms
underlying the upstream regulation of enzymes involved in
nuclear inositol lipid cycle has substantially improved, as evi-
dence reviewed here demonstrates. However, as underscored
in this article, the events that regulate nuclear inositol lipid
metabolism are not necessarily equal to those operating in the
cytoplasm. This makes this ¢eld of investigation all the more
exciting and intriguing. As emphasized by Robin Irvine in his
recent review published in Science’s stke (on line, September
5, 2000), other investigators should enter the fray and ¢nd out
just what is going on within this microcosm of cellular signal-
ing. The contribution of more laboratories would undoubt-
edly expedite the identi¢cation of additional regulatory mech-
anisms of nuclear inositide metabolism. Fundamental to such
a challenge will be to understand how signaling by such a
multitude of proteins is integrated inside the nucleus. In this
regard, the yeast two-hybrid technology has already allowed
the identi¢cation of a protein (PIKE) fundamental for the
regulation of PI3K within the nucleus. The same technique,
if applied for example to nuclear PI-PLC isoforms, might lead
to the identi¢cation of the interacting partners important for
their activation/inhibition. Post-translational modi¢cations of
proteins have already been demonstrated to play a fundamen-
tal role in the control of some aspects of nuclear inositol
metabolism (see also [56]). Therefore, overexpression of other
enzymes mutated in amino acid residues critical for the mod-
i¢cations to occur should improve our understanding of the
exact role played by these changes, even though in some cases
the use of protein overexpression might obscure many of the
subtleties of lipid^protein interactions and their impact under
natural conditions. This very same approach could be applied,
for example, to de¢nitively clarify the biological signi¢cance
of tyrosine phosphorylation of the p85 regulatory subunit of
nuclear PI3K, an issue whose importance is just beginning to
be recognized [57].
Another important outstanding question is to de¢ne to
what extent the complex interplay that exists between the
di¡erent lipid-dependent signaling pathways (e.g. [58]) is op-
erating also in the nucleus and how it is regulated.
A better knowledge of the regulation of nuclear inositol
lipid metabolism appears desirable mostly because, if it will
be determined that at least some molecular mechanisms are
indeed peculiar to the nuclear compartment, this will then
allow pharmaceutical intervention with clinical bene¢ts to hu-
mans through the synthesis of new therapeutic agents having,
as a speci¢c target, the nuclear cycle while sparing the plasma
membrane cycle.
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